ERBB2 and breast cancer: Our group demonstrated that silencing E2F1 or E2F3 suppressed CA/CIN in Her2+ breast cancer, while their overexpression in mammary epithelial cells triggered CA/CIN that respectively correlated with decreases or increases in Nek2 protein levels.